173 related articles for article (PubMed ID: 19067320)
21. Augmenting SRIs for Obsessive-Compulsive Disorder: Patient Preference for Risperidone Does Not Limit Effectiveness of Exposure and Ritual Prevention.
Wheaton MG; Carpenter JK; Kalanthroff E; Foa EB; Simpson HB
Psychother Psychosom; 2016; 85(5):314-6. PubMed ID: 27513584
[TBL] [Abstract][Full Text] [Related]
22. Case study: successful medication withdrawal using cognitive-behavioral therapy for a preadolescent with OCD.
Sallinen BJ; Nangle DW; O'Grady AC
J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1441-4. PubMed ID: 15502604
[TBL] [Abstract][Full Text] [Related]
23. Combination use of atomoxetine hydrochloride and olanzapine in the treatment of attention-deficit/hyperactivity disorder with comorbid disruptive behavior disorder in children and adolescents 10-18 years of age.
Holzer B; Lopes V; Lehman R
J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):415-8. PubMed ID: 23952189
[TBL] [Abstract][Full Text] [Related]
24. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.
Hollander E; Baldini Rossi N; Sood E; Pallanti S
Int J Neuropsychopharmacol; 2003 Dec; 6(4):397-401. PubMed ID: 14604454
[TBL] [Abstract][Full Text] [Related]
25. Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study.
Pfanner C; Marazziti D; Dell'Osso L; Presta S; Gemignani A; Milanfranchi A; Cassano GB
Int Clin Psychopharmacol; 2000 Sep; 15(5):297-301. PubMed ID: 10993132
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive treatment of three patients with comorbid OCPD and ADHD.
Josephson SC; Hollander E; Sumner J
CNS Spectr; 2007 May; 12(5):338-42. PubMed ID: 17514078
[TBL] [Abstract][Full Text] [Related]
27. Quetiapine augmentation of selective serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a six-month follow-up case series.
Dell'Osso B; Mundo E; Altamura AC
CNS Spectr; 2006 Nov; 11(11):879-83; quiz 885. PubMed ID: 17075559
[TBL] [Abstract][Full Text] [Related]
28. Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs.
Ramasubbu R; Ravindran A; Lapierre Y
Pharmacopsychiatry; 2000 Nov; 33(6):236-8. PubMed ID: 11147933
[TBL] [Abstract][Full Text] [Related]
29. Sertraline and obsessive compulsive disorder: new indication. Limited assessment.
Prescrire Int; 2000 Aug; 9(48):112-3. PubMed ID: 11067720
[TBL] [Abstract][Full Text] [Related]
30. Differential efficacy of cognitive-behavioral therapy and pharmacological treatments for pediatric obsessive-compulsive disorder: a meta-analysis.
Sánchez-Meca J; Rosa-Alcázar AI; Iniesta-Sepúlveda M; Rosa-Alcázar A
J Anxiety Disord; 2014 Jan; 28(1):31-44. PubMed ID: 24334214
[TBL] [Abstract][Full Text] [Related]
31. Treatment practices in Tourette syndrome: the European perspective.
Rickards H; Cavanna AE; Worrall R
Eur J Paediatr Neurol; 2012 Jul; 16(4):361-4. PubMed ID: 22178398
[TBL] [Abstract][Full Text] [Related]
32. Cognitive-behavioral group therapy versus sertraline for obsessive-compulsive disorder: five-year follow-up.
Borges CP; Meyer E; Ferrão YA; Souza FP; Sousa MB; Cordioli AV
Psychother Psychosom; 2011; 80(4):249-50. PubMed ID: 21540627
[No Abstract] [Full Text] [Related]
33. [My child is so restless].
Schlamp D
MMW Fortschr Med; 2007 Mar; 149(10):39-40. PubMed ID: 17408047
[TBL] [Abstract][Full Text] [Related]
34. Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series.
Dell'osso B; Mundo E; Marazziti D; Altamura AC
J Psychopharmacol; 2008 Mar; 22(2):210-3. PubMed ID: 18208931
[TBL] [Abstract][Full Text] [Related]
35. Randomized, controlled trial of atomoxetine for attention-deficit/hyperactivity disorder in adolescents with substance use disorder.
Thurstone C; Riggs PD; Salomonsen-Sautel S; Mikulich-Gilbertson SK
J Am Acad Child Adolesc Psychiatry; 2010 Jun; 49(6):573-82. PubMed ID: 20494267
[TBL] [Abstract][Full Text] [Related]
36. Continued cognitive-behavior therapy versus sertraline for children and adolescents with obsessive-compulsive disorder that were non-responders to cognitive-behavior therapy: a randomized controlled trial.
Skarphedinsson G; Weidle B; Thomsen PH; Dahl K; Torp NC; Nissen JB; Melin KH; Hybel K; Valderhaug R; Wentzel-Larsen T; Compton SN; Ivarsson T
Eur Child Adolesc Psychiatry; 2015 May; 24(5):591-602. PubMed ID: 25239489
[TBL] [Abstract][Full Text] [Related]
37. Factors associated with poor response in cognitive-behavioral therapy for pediatric obsessive-compulsive disorder.
Storch EA; Björgvinsson T; Riemann B; Lewin AB; Morales MJ; Murphy TK
Bull Menninger Clin; 2010; 74(2):167-85. PubMed ID: 20545494
[TBL] [Abstract][Full Text] [Related]
38. Obsessive-compulsive symptoms with risperidone.
Mahendran R
J Clin Psychiatry; 1999 Apr; 60(4):261-3. PubMed ID: 10221290
[No Abstract] [Full Text] [Related]
39. Group cognitive-behavioral therapy versus sertraline for the treatment of children and adolescents with obsessive-compulsive disorder.
Asbahr FR; Castillo AR; Ito LM; Latorre MR; Moreira MN; Lotufo-Neto F
J Am Acad Child Adolesc Psychiatry; 2005 Nov; 44(11):1128-36. PubMed ID: 16239861
[TBL] [Abstract][Full Text] [Related]
40. A possible tetracycline-risperidone-sertraline interaction in an adolescent.
Steele M; Couturier J
Can J Clin Pharmacol; 1999; 6(1):15-7. PubMed ID: 10465861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
